Ambys Medicines has raised $60m in a series A round backed by Takeda and signed a strategic partnership agreement with the corporate worth $80m.

Ambys Medicines, a US-based regenerative medicine developer focused on serious liver diseases, may not be a typical spinout but it is the latest company emerging from venture capital firm Third Rock Ventures’ unique “discover, launch, build” model. The approach has the firm collaborate with researchers to identify high-potential projects before helping them launch their company…

The rest of this content is only accessible to Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.